AZ funded Non-clinical PhD Studentship (Fixed Term) in selective nanoparticle targeting of senescent alveolar epithelium using an alveolar organoid model

Develop nanoparticle delivery of senescence-modulating therapies to lung epithelial cells in a Cambridge–AstraZeneca doctoral project. Research uses human alveolar organoids, engineered carriers and automated screening to evaluate drug selection, delivery and functional responses relevant to pulmonary fibrosis. The four-year studentship begins in October 2027.

Applicants need or should expect a first or upper-second-class degree, or overseas equivalent, in a subject that prepares them for cell-biology research. UK citizens and overseas applicants meeting Home-fee requirements may apply; other overseas applicants need additional scholarship funding for the fee difference. Self-funding the difference is not allowed.